Showing results (161-170 of 313) with videos related to

Sort By:
Pageof 32
Cancer|February 18, 2010
Cause of death in patients with lower-risk myelodysplastic syndromeFarshid Dayyani, Anthony P Conley, Sara S Strom, et al.
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|March 15, 2003
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaJorge Cortes, Francis Giles, Susan O'Brien, et al.
Blood|July 14, 2011
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemiaSameer A Parikh, Michael J Keating, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndromeStefan Faderl, Guillermo Garcia-Manero, Zeev Estrov, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapyStefan Faderl, Deborah Ann Thomas, Susan O'Brien, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
British Journal of Haematology|March 28, 2013
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDKoichi Takahashi, Hagop Kantarjian, Naveen Pemmaraju, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Cancer|January 28, 2012
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patientsStefan Faderl, Farhad Ravandi, Xuelin Huang, et al.
Pageof 32